Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | RAMP1 | O60894 | 6/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 6/20 | 0.38 |
| ▸ | NAMPT | P43490 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969189 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CRAMP1CALCRL | |
| SCHEMBL3969190 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CRAMP1CALCRL | |
| SCHEMBL3969212 | 0.95 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CRAMP1CALCRL | |
| SCHEMBL3969209 | 0.95 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CRAMP1CALCRL | |
| SCHEMBL3969213 | 0.95 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CRAMP1CALCRL | |
| SCHEMBL3971422 | 0.91 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CRAMP1CALCRL | |
| SCHEMBL3971419 | 0.91 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CRAMP1CALCRL | |
| SCHEMBL3971416 | 0.91 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CRAMP1CALCRL | |
| SCHEMBL8280162 | 0.90 | CTSB (0.39) | ADRB3ADRA2BADRA2CRAMP1CALCRL | |
| SCHEMBL3968944 | 0.90 | CTSB (0.39) | ADRB3ADRA2BADRA2CRAMP1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRB3 4337/4885ADRA2B 4492/4885ADRA2C 3960/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRB3 4337/4885ADRA2B 4492/4885ADRA2C 3960/4885 |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRB3 4337/4885ADRA2B 4492/4885ADRA2C 3960/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRB3 4337/4885ADRA2B 4492/4885ADRA2C 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.